Keros director receives RSU and option awards

Keros Therapeutics director Nima Farzan reported equity awards that increase his direct stake in the company.

Rhea-AI Filing Summary

Keros Therapeutics director Nima Farzan reported equity awards that increase his direct stake in the company. He received 7,142 shares of common stock through a restricted stock unit (RSU) grant, bringing his direct common stock holdings to 12,392 shares.

The RSUs fully vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, if he continues to provide service. He was also granted a stock option for 7,433 shares at an exercise price of $10.50 per share, vesting in equal quarterly installments over the 12 months following June 3, 2026 and in any case fully vested by the 2027 annual meeting, subject to continued service. These are compensation-related awards rather than open-market purchases or sales.

Insider Trade Summary

Grant/Award: 14,575 shares

Grant/Award 2 txns

Insider Farzan Nima

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	7,433	$0.00	$0.00
Grant/Award	Common Stock	7,142	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 7,433 contracts (Direct); Common Stock — 12,392 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.
2. F2. The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

Key Figures

RSU grant size: 7,142 shares Option grant size: 7,433 shares Option exercise price: $10.50 per share +3 more

6 metrics

RSU grant size 7,142 shares Restricted stock unit award vesting by June 3, 2027 or 2027 meeting

Option grant size 7,433 shares Stock option covering common stock

Option exercise price $10.50 per share Stock option (right to buy) exercise price

Shares after RSU grant 12,392 shares Common stock directly held following non-derivative transaction

Option expiration June 2, 2036 Stock option expiration date

RSU vesting deadline June 3, 2027 Latest vesting date or earlier 2027 annual meeting

Key Terms

restricted stock unit ("RSU"), Stock Option (right to buy), vesting, annual meeting of stockholders

4 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027..."

Stock Option (right to buy) financial

"Stock Option (right to buy) with an exercise price of $10.5000 per share..."

vesting financial

"The option shall vest in equal quarterly installments over the 12 months following June 3, 2026..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders financial

"the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service..."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Nima Farzan report at Keros Therapeutics (KROS)?

Nima Farzan reported receiving equity awards from Keros Therapeutics, including 7,142 restricted stock units and a stock option for 7,433 shares. These are compensation-related grants, not open-market share purchases or sales, and increase his potential ownership in the company over time.

How many Keros Therapeutics shares does Nima Farzan hold after this Form 4?

After the RSU grant, Nima Farzan holds 12,392 shares of Keros Therapeutics common stock directly. This figure reflects his reported non-derivative holdings following the award and does not include shares that may be acquired later through exercising the newly granted stock option.

What are the key terms of Nima Farzan’s RSU award from Keros Therapeutics (KROS)?

The RSU award covers 7,142 shares and fully vests on the earlier of June 3, 2027 or Keros Therapeutics’ 2027 annual meeting of stockholders. Vesting is conditioned on Nima Farzan continuing to provide service to the company through the applicable vesting date.

What are the details of the stock option grant reported by Nima Farzan at Keros Therapeutics?

Nima Farzan received a stock option for 7,433 shares of Keros Therapeutics common stock at a $10.50 exercise price. The option vests in equal quarterly installments over 12 months after June 3, 2026 and will be fully vested by the 2027 annual meeting, subject to continued service.

Are Nima Farzan’s reported Keros Therapeutics transactions open-market buys or sells?

The transactions are not open-market buys or sells. They are equity compensation awards: a restricted stock unit grant and a stock option grant. Both are classified as grant or award acquisitions and depend on continued service for vesting, rather than market trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/05/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farzan Nima

(Last) (First) (Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON MASSACHUSETTS 02421

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		A		7,142(1)	A	$0	12,392	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.5	06/03/2026		A		7,433		(2)	06/02/2036	Common Stock	7,433	$0	7,433	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

2. The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person continuing to provide service through each such date.

	/s/ Keith Regnante, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)